References
- Chapman PB , HauschildA, RobertCet al. improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
- Westin JR , KurzrockR. It‘s about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol. Cancer Ther.11(12), 2549–2555 (2012).
- Noda K , NishiwakiY, KawaharaMet al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85–91 (2002).
- Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
- Albert R , BarabásiAL. Statistical mechanics of complex networks. Rev. Mod. Physics74(1), 47–97 (2002).
- Albert R , JeongH, BarabasiAL. Error and attack tolerance of complex networks. Nature406(6794), 378–382 (2000).
- Newman M , BarabásiAL, WattsDJ. The structure and dynamics of networks. Princeton University Press, NJ, USA (2011).
- Albert R , JeongH, BarabásiAL. Diameter of the world-wide web. Nature401(6749), 130–131 (1999).
- Ravasz E , SomeraAL, MongruDA, OltvaiZN, BarabásiAL. Hierarchical organization of modularity in metabolic networks. Science297(5586), 1551–1555 (2002).
- Schneeberger A , NatR, MercerCHet al. Scale-free networks and sexually transmitted diseases: a description of observed patterns of sexual contacts in Britain and Zimbabwe. Sex. Transm. Dis. 31(6), 380–387 (2004).
- Barabási AL , JeongH, NédaZ, RavaszE, SchubertA, VicsekT. Evolution of the social network of scientific collaborations. Physica A311(3–4), 590–614 (2002).
- Reggiani A , NijkampP, CentoA. Connectivity and concentration in airline networks: a complexity analysis of Lufthansa‘s network. Eur. J. Inf. Syst.19(4), 449–461 (2010).
- Margolin AA , NemenmanI, BassoKet al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7(Suppl. 1), S7 (2006).
- Vogelstein B , PapadopoulosN, VelculescuVE, ZhouS, DiazLA, KinzlerKW. Cancer genome landscapes. Science339(6127), 1546–1558 (2013).
- Villanueva J , VulturA, HerlynM. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res.71(23), 7137–7140 (2011).
- Kopetz S DJ , ChanE, HechtJRet al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol.28, 15s (2010).
- Prahallad A , SunC, HuangSet al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387), 100–103 (2012).
- Corcoran RB , EbiH, TurkeABet al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2(3), 227–235 (2012).
- Mao M , TianF, MariadasonJMet al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res. 19(3), 657–667 (2013).